Hodinový prehľad - Zdravotnícke a vedecké zaujímavosti

Súhrn: Olezarsen received priority review and breakthrough therapy designations for this indication An integrated analysis of the two trials found that treatment with olezarsen significantly reduced the rate of acute pancreatitis compared with placebo The US FDA has approved olezarsen (Tryngolza, Ionis Pharmaceuticals), in combination with diet, to reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Súhrn: TOPLINE: A single infusion of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, produces decade-long remissions in approximately one third of patients with heavily pretreated large B-cell lymphomas and nearly half of those with follicular lymphoma The durability of remissions beyond 5 years and the curative potential of CAR T-cell therapy remain unclear, as late recurrences after chemoimmunotherapy are well recognized in lymphoma patients - Researchers evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 with large B-cell lymphoma and 14 with follicular lymphoma) who received CTL019 (now called tisagenlecleucel) at the University of Pennsylvania in Philadelphia.